ANN ARBOR – Marty Makary, head of the U.S. Food and Drug Administration (FDA) reported the agency will not interfere with a new federal policy providing Medicare beneficiaries coverage for hemp-derived CBD products.
Makary said while the agency preserves its authority to regulate products containing hemp or hemp-derived compounds under the Food, Drug and Cosmetic (FD&C) Act, it will loosen its “enforcement posture” for certain CBD products eligible under the Centers for Medicare and Medicaid Services’ (CMS) CBD pilot program that commenced on April 1.
Kyle McCalmon, co-owners of Thumb Coast CBD in St. Clair, joins Mike Brennan, editor of MITechNews, and Dave Crabill, iHemp Michigan board member, on this episode of Michigan Marijuana Today to explain what this means for CBD.
The new policy allows up to $500 per year in coverage of doctor-recommended CBD products containing no more than 0.3% delta-9 THC and no more than 3 milligrams per serving of total THC (including delta-8, delta-10 and THCA) in orally transmitted form. Inhalable products are “expressly excluded.”
Coinciding with the CMS pilot program launch, Makary sent the letter clarifying the FDA’s enforcement discretion to Kyle Diamantas, the FDA’s deputy commissioner for human foods, and Dr. Tracy Beth Høeg, the FDA’s acting director of the Center for Drug Evaluation and Research.
Watch this video to get all the details.
You can also order CBD products at www.thumbcoastcbd.com.
